From the blog

Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients

Published: June 4, 2013

Primary Outcome Measures:

  • Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR. [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) . [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Eligibility Criteria

Study Population
Malignant pleural mesothelioma patients treated with vinorelbine as a second or later line chemotherapy with at least an objective response evaluation.
Inclusion Criteria:
  • MPM patients treated with vinorelbine in the ≥ second line setting will be retrospectively analyzed
  • Patients will be selected based on the availability of tumor tissue
Exclusion Criteria:
Contact Us
Have you received a diagnosis? *